Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases.Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019. 

Novo Seeds

Anthos Therapeutics

Anthos Therapeutics’ CEO John Glasspool joined host Karen Jagoda on the #EmpoweredPatient Podcast. They discuss the bleeding risk associated with current #anticoagulants, and the potential benefits that a #hemostasis sparing #anticoagulant could offer patients. 

Listen: https://bit.ly/3L7FDfO

#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Anthos Therapeutics’ CEO John Glasspool spoke with Daniel Levine about the development of #abelacimab, and the potential to uncouple the pathways for #thrombosis and #hemostasis by targeting #FactorXI.

Listen on #TheBioReport Podcast: https://bit.ly/3KRZxuR

#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Anthos Therapeutics’ CMO Dan Bloomfield, MD, FACC, FAHA recently joined NPR’s Tech Nation, hosted by Moira Gunn, to discuss the current unmet needs in #anticoagulation and #abelacimab’s ability to provide effective anticoagulation with the potential for a lower bleeding risk.

Listen: https://bit.ly/3JzrtlQ
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Despite being a leading cause of death and disability worldwide, many people are unaware of venous #thromboembolism (VTE) and its associated health risks.
 
Educate yourself and others about #VTE with resources from WorldThrombosisDay & the International Society on Thrombosis and Haemostasis (ISTH): https://bit.ly/33SFSrY
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Anthos Therapeutics is developing the novel dual activity agent #abelacimab to target both #FactorXI and #FactorXIa, with the potential to turn our vision of hemostasis sparing #anticoagulation into reality.

Learn more about the promise of #FactorXI inhibition: https://bit.ly/3pZXcph

#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

According to the Centers for Disease Control and Prevention, 10 to 30% of people will die within one month of being diagnosed with venous thromboembolism. Our goal is to improve patient outcomes by developing a novel #anticoagulant with the potential to provide hemostasis-sparing anticoagulation.

Learn more about #VTE: https://bit.ly/3tL5aUz

#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

#ICYMI – Anthos Therapeutics CEO John Glasspool joined host Matthew Pillar on the BioProcess Online #BusinessOfBiotech #Podcast to discuss the clinical development of abelacimab and the potential for pipeline expansion to other areas of unmet need.
 
Listen: https://lnkd.in/dWh96btM
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

We are pleased to announce that CEO John Glasspool was appointed to the Biotechnology Innovation Organization Board of Directors. John’s vast biotech experience and passion for helping patients will support BIO’s mission to drive a biotech revolution through education, collaboration, and advocacy.
 
Learn more: https://lnkd.in/gE69pKG
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

February is #AmericanHeartMonth, a time to focus on #cardiovascular health and educate others about the risks of #HeartDisease. Anthos Therapeutics is a clinical stage #biopharma company committed to improving outcomes for patients with cardiovascular and metabolic diseases.
 
Get involved: https://lnkd.in/eETWjdV
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Viewport Meta

IPhone / Mobile Compatible

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

WordPress

Global Site Tag

Mobile Non Scaleable Content

Sitelinks Search Box

Chief Medical Officer

Dan Bloomfield

Information Technology

Dr Sanobar Parkar

Operations

Janeen Salter

Program and Project Management

Erika Dahl

Healthcare

Bruce Hug

Finance and Administration

David McIntyre

Deb Freedholm

Sales and Support

Drew Young

Gi Gi Galiano

William P. Kane

President and CCO

William Meury

Mia Kelley

General Counsel

John Glasspool

CEO & President

Laurel Ostrom

CHRO

Venkat Ramanan

Chief Financial Officer

Jonathan Freeman

Therapeutics Early Stage Companies With Fewer Than 50 Employees

East Coast Early Stage Companies With Fewer Than 100 Employees

Northeastern US Companies With Fewer Than 50 Employees (Top 10K)

Massachusetts Therapeutics Companies

Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases. The company was founded by a world-class executive team with extensive experience in the development and commercialization of CVM disease therapies.

Series A - Anthos Therapeutics

Venture Round - Anthos Therapeutics

Cambridge

Massachusetts

United States

North America

Analysis finds abelacimab cuts bleeding in patients on APT versus rivaroxaban

Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer

Anthos Therapeutics Appoints Mia Kelley as General Counsel and Laurel Ostrom as Chief Human Resources Officer

Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke

Changing Faces: Pharma and biotech hires from April 2024

First-Ever Cost-Effectiveness Analysis of a Factor XI Inhibitor Demonstrates that Abelacimab, if Approved, Could Offer ...

Biotech CEO: Bayh-Dole 'fix' won't lower drug prices

Anthos Therapeutics Announces Appointment of Bill Meury as CEO

An investigational monoclonal antibody that inhibits Factor XI and XIa, designed to provide anticoagulation with reduced bleeding risk for the prevention and treatment of arterial and venous thromboembolic events.

The Netherlands

Europe

Bangladesh

Asia

Mexico

Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	d9a388c7
crunchbase profile	general	Nov 25, 2024 12:08 PM	f5d90800
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 1:57 PM	3cc95894
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ANTHOSTHERAPEUTICS

Anthos Therapeutics